XNASQTTB
Market cap39mUSD
Jan 08, Last price
3.27USD
1D
-7.37%
1Q
-93.07%
Name
Q32 Bio Inc
Chart & Performance
P/E
—
P/S
33.75
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.16%
Rev. gr., 5y
-26.32%
Revenues
1m
-82.62%
Net income
-113m
L+163.87%
CFO
-96m
L+778.25%
Earnings
Mar 11, 2025
Profile
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 1,156 -82.62% | 6,651 -80.42% | ||||||
Cost of revenue | 62,580 | 48,475 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (61,424) | (41,824) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 25,881 | 62 | ||||||
Tax Rate | ||||||||
NOPAT | (87,305) | (41,886) | ||||||
Net income | (112,961) 163.87% | (42,809) 13.96% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 184 | 69 | ||||||
BB yield | -0.52% | -0.10% | ||||||
| Debt | ||||||||
Debt current | 1,318 | 32,873 | ||||||
Long-term debt | 19,115 | |||||||
Deferred revenue | 11,318 | |||||||
Other long-term liabilities | (1) | 111,445 | ||||||
Net debt | (81,335) | (17,719) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (96,230) | (10,957) | ||||||
CAPEX | (228) | (2,485) | ||||||
Cash from investing activities | 101,326 | (2,466) | ||||||
Cash from financing activities | 184 | 30,069 | ||||||
FCF | (78,789) | (50,849) | ||||||
| Balance | ||||||||
Cash | 82,653 | 43,893 | ||||||
Long term investments | 25,814 | |||||||
Excess cash | 82,595 | 69,374 | ||||||
Stockholders' equity | (542,097) | (133,337) | ||||||
Invested Capital | 616,406 | 169,549 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 3,213 | 3,189 | ||||||
Price | 10.94 -51.75% | 22.68 -65.38% | ||||||
Market cap | 35,164 -51.38% | 72,324 -64.06% | ||||||
EV | (46,171) | 55,009 | ||||||
EBITDA | (60,846) | (41,454) | ||||||
EV/EBITDA | 0.76 | |||||||
Interest | ||||||||
Interest/NOPBT | ||||||||